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creativecommons.org/licenses/by-nc-nd/Abstract In Europe, almost 1000 children are diagnosed with a malignant renal tumour each
year. The vast majority of cases are nephroblastoma, also known as Wilms’ tumour (WT).
Most children are treated according to Socie´te´ Internationale d’Oncologie Pe´diatrique Renal
Tumour Study Group (SIOP-RTSG) protocols with pre-operative chemotherapy, surgery,
and post-operative treatment dependent on stage and histology. Overall survival approaches
90%, but a subgroup of WT, with high-risk histology and/or relapsed disease, still have a much
poorer prognosis. Outcome is similarly poor for the rare non-WT, particularly for malignant
rhabdoid tumour of the kidney, metastatic clear cell sarcoma of the kidney (CCSK), and met-
astatic renal cell carcinoma (RCC).
Improving outcome and long-term quality of life requires more accurate risk stratification
through biological insights. Biomarkers are also needed to signpost potential targeted thera-
pies for high-risk subgroups. Our understanding of Wilms’ tumourigenesis is evolving and
several signalling pathways, microRNA processing and epigenetics are now known to play
pivotal roles. Most rhabdoid tumours display somatic and/or germline mutations in the
SMARCB1 gene, whereas CCSK and paediatric RCC reveal a more varied genetic basis,
including characteristic translocations. Conducting early-phase trials of targeted therapies is
challenging due to the scarcity of patients with refractory or relapsed disease, the rapid pro-
gression of relapse and the genetic heterogeneity of the tumours with a low prevalence of in-
dividual somatic mutations. A further consideration in improving population survival rates is
the geographical variation in outcomes across Europe.n, University College London, Institute of Child Health, UK.
Brok).
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lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
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J. Brok et al. / European Journal of Cancer 68 (2016) 179e195180This review provides a comprehensive overview of the current biological knowledge of
childhood renal tumours alongside the progress achieved through international collaboration.
Ongoing collaboration is needed to ensure consistency of outcomes through standardised di-
agnostics and treatment and incorporation of biomarker research. Together, these objectives
constitute the rationale for the forthcoming SIOP-RTSG ‘UMBRELLA’ study.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Childhood renal tumours account for around 7% of all
childhood cancers. The majority of cases (90%) are
Wilms’ tumour (WT or nephroblastoma), with an
annual incidence of approximately 1 in 100,000 children
[1]. Thus, a large European country, such as Germany,
will experience around 100 new cases a year, whereas a
small country like Denmark diagnose less than 10 cases
annually.
The median age at diagnosis of WT is 3 years but
bilateral cases and those associated with congenital
syndromes occur earlier. The most common presenta-
tion is that of an abdominal mass or swelling, and
children are usually otherwise clinically well [2]. Other
symptoms include abdominal pain, haematuria, fever,
and symptoms related to hypertension. About 10% of
WT have haematogenous spread, most commonly to the
lungs (85%), liver (10%) and only very rarely to the
bones and brain [1].
WT may occur as a part of a genetic predisposition
syndrome in 5e10% of cases. The more common phe-
notypes include WAGR (WT, aniridia, genitourinary
anomalies, and mental retardation), DenyseDrash
syndrome, BeckwitheWiedemann syndrome, asym-
metric overgrowth, or family history of WT [3]. If pre-
disposition is suspected prior to the diagnosis of WT,
the tumour may be detected through a screening
programme.
The most frequently occurring non-Wilms’ renal tu-
mours (non-WT) include clear cell sarcoma of the kid-
ney (CCSK) with an identical age distribution to WT,
malignant rhabdoid tumour of the kidney (MRTK) with
a peak incidence between the age of 10e18 months and
renal cell carcinoma (RCC), which usually occurs in
adolescence. Altogether, CCSK and MRTK comprise
about 3e5% of all primary renal tumours in children,
whereas RCC accounts for around 1% (Fig. 1) [4]. Other
types of malignant renal tumours, such as anaplastic
sarcoma and primitive neuroectodermal tumour of the
kidney, are extremely rare. Overall non-WT have a
poorer outcome than WT. Relatively benign renal tu-
mours, such as congenital mesoblastic nephroma, are
mainly diagnosed in newborns or during foetal anomaly
scanning, and cure can usually be achieved with surgery
alone.There are two different approaches to the initial
management of renal tumours in childhood. Most
children in Europe are treated with pre-operative
chemotherapy, according to the Socie´te´ Internationale
d’Oncologie Pe´diatrique Renal Tumour Study Group
(SIOP-RTSG) protocols. In North America, patients
are treated with upfront surgery prior to administra-
tion of chemotherapy, as per the National Wilms’
Tumour Study/Children’s Oncology Group (COG)
protocols. Although the SIOP and COG strategies
differ in their upfront treatment approach, they have a
similar overall survival (OS) of nearly 90% [5,6].
Despite the excellent prognosis for most children
with WT, just under 15% of patients will relapse,
usually within 2 years of diagnosis [5]. Furthermore, a
proportion of patients will experience severe early and
late treatment-related adverse events, e.g. cardiotox-
icity secondary to doxorubicin (DOX) or radiotherapy-
induced organ dysfunction, musculoskeletal abnor-
malities, infertility and secondary malignancies [7,8].
The current aims of treatment optimisation are to
standardise diagnosis, to improve risk stratification, to
minimise side-effects of treatment and to improve
relapse monitoring according to clinical, molecular,
histopathological and imaging data.
The aim of this review is to provide the clinician with
an overview of tumour biology, current treatment and
research into more effective therapies for subgroups of
paediatric renal tumours. Focus will be on WT, due to
its relatively higher incidence, but other renal tumours
will be discussed within the context of the SIOP-RTSG
strategy.2. Biology of sporadic WT and predisposition syndromes
2.1. Genetics
Despite our incomplete understanding of the patho-
genesis of WT, there is increasing evidence that several
signalling pathways, microRNA processing, and epige-
netics all play pivotal roles (Table 1). In general, WT
represent a genetically heterogeneous group, displaying
a low prevalence of known somatic alterations and a
high degree of intra-tumoural heterogeneity [9].
The first WT-related gene to be characterised was
WT1, a zinc finger DNA-binding transcription factor,
Table 1
Most frequently identified somatic changes in childhood renal tumours.
Genetics Tumour Approximate incidence Clinicopathological associations References
WT1 (11p13) WT 10e20% Early event, found in ILNR;
associated with stromal histology
[11,15]
CTNNB1 (3p21) WT 15% Late event, not in NR [16]
MLLT1 (19p13) WT 4% in one series Early event, found in ILNR; younger
age
[18]
WTX (Xq11) WT 15e20% No clinicopathological associations [19,21]
IGF2 (11p15) WT 69% Early event, found in PLNR;
associated with epithelial/blastemal
histology
[14,38]
Loss of 1p, 16q WT 1p 11%; 16q 17%; 1p/16q
5%
Combined LOH associated with
reduced EFS and OS
[6]
Gain of 1q WT 27% Reduced EFS, possible reduced OS [106,107,108]
TP53 (17p13) WT 70% of anaplastic tumours Reduced EFS and OS; rarely found in
tumours without diffuse anaplasia
[24,27]
MYCN (2p24) WT 13% Reduced EFS, OS; associated with
anaplastic histology
[31]
miRNAPG: DROSHA,DGCR8,
DICER1, TARBP2, DIS3L2
and XPO5
WT 18% of SIOP high-risk
blastema tumours
15% pre-therapy FHWT
Found in PLNR in FHWT; DGCR8
has a female bias (88% of cases)
reduced EFS, OS when found in
combination with SIX1/2 mutations
[25,32,42]
SIX1 (14q23), SIX2 (2p21) WT 18% of SIOP high-risk
blastema tumours
7% pre-therapy FHWT
Found in PLNR in FHWT; reduced
EFS and OS when found in
combination with miRANPG
mutations
[25,32]
SMARCA4 (19p13) WT ATRT 4.5% in one series 1 case
report
Not known [42,69]
SMARCB1(22q11) MRTK ATRT 95% Mutation found in almost all patients [64,65]
YWHAE-NUTM2 t(10;17)
(q22;p13)
CCSK 12% No clinicopathological associations [54,58]
ITD BCOR (Xp11) CCSK 85e100% Not known [59,60]
TFE3 (Xp11) to ASPL (17q25),
PRCC (1q21), PSF (1p34),
NonO (Xq12), and CLTC
(17q23)
RCC 20e40% Translocation-type RCC [72]
TFEB t(6;11) (p21;q12) RCC Case reports Translocation-type RCC [73]
ATRT, atypical teratoid/rhabdoid tumour; CCSK, clear cell sarcoma of the kidney; EFS, event-free survival; FWHT, favourable histology Wilms’
Tumour; ILNR, intralobar nephrogenic rests; LOH, loss of heterozygosity; OS, overall survival; PLNR, perilobar nephrogenic rests; PLNR,
perilobar nephrogenic rests; RCC, renal cell carcinoma; SIOP, Socie´te´ Internationale d’Oncologie Pe´diatrique; WT, Wilms’ tumour.
Fig. 1. Distribution of renal tumours in children registered in the SIOP-RTSG WT 2001 trial and study. Note that MRTK and RCC are
underrepresented in this clinical database, compared to population-based cancer registration [165]. CCSK, clear cell sarcoma of the
kidney; CMN, congenital mesoblastic nephroma; MRTK, malignant rhabdoid tumour of the kidney; RCC, renal cell carcinoma; WT,
Wilms’ tumour.
J. Brok et al. / European Journal of Cancer 68 (2016) 179e195 181
J. Brok et al. / European Journal of Cancer 68 (2016) 179e195182with a vital role in nephrogenesis and glomerular func-
tion in the mature kidney [10e12]. Germline WT1 mu-
tations lead to a range of genitourinary malformations
and underlie tumour development in both WAGR and
DenyseDrash syndromes [13]. Approximately 5e20%
of sporadic tumours also exhibit somaticWT1 loss, with
incidence dependent on patient ethnicity [14]. Mutations
in WT1 are also found in precursor lesions known as
intralobar nephrogenic rests (ILNR), suggesting that
they are early events in tumourigenesis [15].
WT1 negatively regulates the WNT pathway and
mutations in the CTNNB1 gene, coding for the crucial
protein beta-catenin, often occur alongside WT1 loss
[16,17]. Recently, somatic mutations in theMLLT1 gene
were identified in 4% of WT, frequently accompanied by
CTNNB1 mutations and WNT pathway activation [18].
MLLT1 plays a critical role in transcriptional regulation
during early renal developmental and patients with the
mutation present at a younger age with a high preva-
lence of ILNR.
Beta-catenin is targeted for degradation by the
’destruction complex’ which includes the WTX
(AMER1) protein, this is itself inactivated in 18% of
WTs [19e21]. The role of somatic WTX mutations in
tumour development is unclear and germline mutations,
found in sclerosing skeletal dysplasia, confer no
increased risk of WT [22]. WTX interacts with the
tumour suppressor protein p53, enhancing its role in cell
cycle arrest and apoptosis [23].
Somatic mutations in TP53 are only found in
approximately 70% of the rare high-risk group of
anaplastic cases [24]. These tumours have a characteris-
tically unstable genome with multiple copy number ab-
errations and chromothripsis [25]. In addition to the
classical role of p53 as a tumour suppressor protein,
gain-of-function mutations are now thought to drive cell
migration and invasion [26]. In WT, mutations in TP53
are an independent indicator of poor prognosis [27].
Another protein thought to hold tumour suppressor
function is the RE1 Silencing Transcription Factor
(REST) transcription factor, and inactivating mutations
have been identified in both sporadic and familial WT
[28]. REST is a transcriptional repressor that is essential
for embryonic development and truncations in the pro-
tein occur in several cancers [29].
Regarding driver genes, gain of the proto-oncogene
MYCN is associated with poor outcome in several
childhood embryonal cancers including WT, neuro-
blastoma, medulloblastoma and rhabdomyosarcoma
[30]. Gain of MYCN is predominantly a somatic event
but germline aberrations have also been reported [31].
SIX1 and SIX2 were also recently identified as other
prognostically relevant candidate oncogenes, with so-
matic mutations found in both low- and high-risk his-
tological subtypes [25,32]. These transcription factors
are known to be involved in nephron development, withSIX2 maintaining mesenchyme progenitor cells in an
undifferentiated blastema state and SIX1-knockout
mice displaying renal agenesis [33,34].
2.2. Epigenetics
Disruption of epigenetic processes, such as DNA
methylation and histone modification, is now known to
contribute to the development and progression of many
childhood solid tumours including WT [35,36].
Through analysis of patients with Beck-
witheWiedemann and related overgrowth syndromes,
aberrant imprinting at 11p15 was implicated in WT
development. The twoprincipal abnormalities at this locus
are paternal uniparental disomy and maternal H19 epi-
mutation, both resulting in activation of the insulin-like
growth factor (IGF) signalling pathway [37]. This is the
most common pathway that is deregulated in WT, with
somatic aberrations found in 70% of sporadic tumours,
and is considered to occur early in tumour development
[14,38]. TheseWTare a clinically distinct group from those
without the mutation and are associated with blastema/
epithelial histology and perilobar nephrogenic rests [39].
The IGF pathway is involved in cell proliferation, inhibi-
tion of apoptosis and protein synthesis, via activation of
the phosphatidylinositol 3-kinase/Akt/mammalian target
of rapamycin (P13K/Akt/mTOR) and raserafemitogen-
activated protein kinases (MAPK) signalling [40].
Many other changes to the epigenome have been
identified in WT. Whole-exome sequencing has
demonstrated mutations in the chromatin remodelers
SMARCA4 and ARIDIA, previously identified in
childhood medulloblastoma [41,42]. Analysis of
methylation profiles shows significant variation between
normal kidney, nephrogenic rests and tumour [43]. In
addition, promoters for SIX2 and WT1 are hypo-
methylated in WT and foetal kidneys; in contrast,
hypermethylation of these sequences is described in
mature kidneys [44]. WT1 itself can directly affect
methylation through transcriptional regulation of the
enzymes DNA methyltranferase 3A and DNA methyl-
transferase 1 [45,46]. WT1 also recruits Polycomb pro-
teins to reduce Pax2 expression, a transcriptional
regulator that is critical for urogenital development and
mesenchymal-to-epithelial transition (MET) [47]. Poly-
comb genes (EZH2, BMI-1 and SUZ12) are upregulated
in WT xenografts and reduced when tumour cells un-
dergo differentiation, suggesting that they may maintain
malignant renal progenitor cells [44].
2.3. MicroRNA processing pathway
MicroRNAs (miRNAs) are small non-coding RNAs
involved in post-transcriptional gene silencing [48].
Mutations in several miRNA-processing genes (DRO-
SHA, DICER1, DGCR8, XPO5 and TARBP2) have
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naive tumours and post chemotherapy [25,32,42].
DROSHA and DICER1 mutations reduce expression of
the tumour-suppressor Let7 family and lead to failure of
epithelial differentiation [42]. Disruption of miRNA
biogenesis through germline mutations in DIS3L2 un-
derlies Perlman syndrome, a rare congenital overgrowth
syndrome with susceptibility to WT [49]. In addition to
tumour development, specific miRNAs can predict
response to chemotherapy and are associated with
metastasis, suggesting a role in disease progression
[50,51]. Several groups have explored their use as a
diagnostic biomarker, demonstrating that serum
miRNA profiles can reliably differentiate WT from
other solid tumours and healthy controls [52,53].3. Biology of non-WT
3.1. Clear cell sarcoma of the kidney
CCSK is not associated with genetic predisposition syn-
dromes and familial CCSK cases have not been reported.
One of the recurring genetic changes is the translocation
t(10;17) (q22;p13), occurring in about 12% of tumours
[54]. This involves the fusion of YWHAE andNUTM2B/
E genes on chromosome 17 and 10, respectively. The
YWHAE gene encodes an epsilon protein, which mod-
ulates phosphoserine-containing proteins and plays a
role in various signal transduction pathways including
P13K/Akt and MAPK [55e57]. This translocation does
not appear to be correlated with either tumour charac-
teristics or patient outcome [58].
Recently, recurrent internal tandem duplications
(ITD) of the X-linked BCL-6 co-repressor (BCOR) gene
have been described and are found to be mutually
exclusive to t(10;17) (q22;p13) [59,60]. Until recently, all
reported CCSK patients without t(10;17) (q22;p13) were
thought to harbour the BCOR ITD and vice versa, but a
subset of tumours have been identified with neither
mutation [61]. Finally, although CCSK is a genomically
stable tumour, over-expression of several genes has been
reported, including neural markers (e.g. nerve growth
factor receptor) and genes involved in both the Sonic
hedgehog pathway and the P13K/Akt cell proliferation
pathway [62,63].3.2. Malignant rhabdoid tumour of the kidney
More than 95% of rhabdoid tumours have bi-allelic
inactivating mutations of SMARCB1. Up to 35% of
patients also have a germline mutation in one allele of
SMARCB1, which is an additional adverse prognostic
indicator [64e68]. SMARCA4 mutations have been
identified in a smaller subset of patients with the closely
related atypical teratoid/rhabdoid tumour of the
brain [69]. SMARCB1 encodes a member of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin
remodelling complex, which regulates transcription of
specific targets. Germline analysis is recommended for
individuals of all ages with rhabdoid tumours and pre-
natal diagnosis can be performed in families with a
known SMARCB1 alteration. Surveillance guidelines
for patients with a germline mutation have been devel-
oped [70]. Gene expression studies of rhabdoid tumour
have identified multiple other genes and pathways with
altered expression [71].3.3. Renal cell carcinoma
In children, translocation RCC is the most common
subtype of RCC and is characterised by translocations
involving the transcription factor E3 gene (TFE3) on
chromosome Xp11. This gene can fuse to several part-
ners including ASPL (17q25), PRCC (1q21), PSF
(1p34), NonO (Xq12), and CLTC (17q23) [72]. Another
less-common translocation is t(6;11) (p21;q12) involving
a fusion of Alpha (11q12) and transcription factor EB
(TFEB) (6p21) that leads to overexpression of TFEB
[73]. Of interest, 15% of patients with translocation RCC
have previously been treated with chemotherapy [74].
Several genetic syndromes are associated with a pre-
disposition to RCC. The best described is von Hippel-
Lindau (VHL), caused by mutations or deletions in the
VHLgene.VHL is a tumour suppressor gene that regulates
the level of the hypoxia-inducible factor family of tran-
scription factors and is involved inmany cellular processes
that are dysregulated in human cancer [75]. Affected in-
dividuals are mainly susceptible to clear cell type RCC.
Tumours usually develop in adulthood, only rarely in
childhood, and annual screening is recommended [70].
Tuberous sclerosis (TS) is another rare genetic syn-
drome that carries an increased risk of both RCC of the
clear cell type and angiomyolipoma. The syndrome is
caused by mutations in the TSC1 and TSC2 genes, which
encode key regulators of the mTOR pathway [76]. Mu-
tations in the FLCN gene, encoding the protein folliculin
which interacts with the mTOR pathway, underlie the
BirteHoggeDube´ syndrome [77]. Individuals with this
syndrome are at risk of developing hybrid oncocytoma/
chromophobe RCC. Mutations in the MET oncogene,
encoding the hepatocyte growth factor receptor, lead to
hereditary papillary RCC [78]. Children with germline
mutations of two tricarboxylic acid (Krebs) cycle genes,
fumarate hydratase (FH) and succinate dehydrogenase
(SDH), are also susceptible to RCC [79].4. Current models of tumours
4.1. Genetically modified mouse models
Much effort has been directed towards preclinical
models to further characterise Wilms’ tumourigenesis
J. Brok et al. / European Journal of Cancer 68 (2016) 179e195184and to guide drug discovery. The identification of WT1
in 1990 led to the development of early WT1-knockout
mouse models [80]. Mice with homozygous loss dis-
played complete renal agenesis, dying prematurely,
whilst those with a heterozygous genotype did not
develop tumours. The first sustainable WT mouse model
was developed in 2011 with WT1 loss, leading to failure
of MET of the metanephric blastema, and upregulation
of IGF2 resulting in arrested differentiation and cellular
proliferation [81]. A second murine model arose from
the finding that Lin28 overexpression during kidney
development prevents the final stage of differentiation,
leading to WT formation in mice [82]. Lin28 is an RNA-
binding protein that suppresses Let-7 miRNA process-
ing and has also been implicated in the development of
neuroblastoma and type II germ cell tumours [83,84].4.2. Cell lines
Development of cell lines with a sustained life span that
are representative of the triphasic histological pattern of
Wilms has been challenging, with many attempts found
to represent other tumour types. The WiT49 anaplastic
cell line, from a xenograft of a human WT lung metas-
tasis, is stable with biphasic histology. It carries a TP53
mutation, overexpresses IGF2 and has wild-type WT1,
with a high tumour occurrence rate when transplanted
into recipient mice [85]. The cell line has been used to
demonstrate that overexpression of SIX2 shifts WNT/b-
catenin signalling away from differentiation and to-
wards stem cell survival and that the sphingosine-1-
phosphate (S1P) pathway stimulates cell migration and
invasion [86,87]. Initial testing of novel compounds has
been carried out on WT and rhabdoid cell lines, pre-
dominantly by the paediatric preclinical testing pro-
gramme, a North American initiative that evaluates
novel compounds in solid tumour and leukaemia in vivo
models. Encouraging results have recently been reported
for WT with inhibitors of JAK1/2, topoisomerase II and
exportin 1 [88e90]. The exportin 1 inhibitor selinexor
demonstrated additional cytotoxic activity with rhab-
doid cell lines, although all rhabdoid xenografts had
progressive disease [90]. Unfortunately, for CCSK, it
has not yet been feasible to grow cell lines.4.3. Novel models
Organoids are 3D adult organ-derived epithelial struc-
tures that contain self-renewing and organ-specific stem
or progenitor cells, as well as differentiated cells [91].
Organoid cultures have proven to be of value for basic
research, for the study of healthy tissue homeostasis and
biology of disease. Kidney organoid systems are
currently being developed for functional validation
studies and preclinical drug testing of paediatric renal
tumours [92].In addition, the zebrafish has emerged as an excellent
model for studies of vertebrate biology. External
development and optical transparency during embryo-
genesis allow for visual analysis of early developmental
processes, and high fecundity and short-generation time
facilitate genetic analysis. The organisms have been used
to study the effect of WT-related gene knockdowns on
nephrogenesis and have confirmed the essential roles of
WT1 and SIX2 [93,94]. More recently, zebrafish have
provided insight into many human tumours and their
role as a WT model remains promising [95].5. Upcoming European SIOP-RTSG clinical study
For more than a decade, the SIOP-RTSG WT-2001 has
been the main clinical trial and study enrolling children
with renal tumours in Europe. This randomised clinical
trial (RCT) has further optimised risk-stratified chemo-
therapy to omit DOX in stage II/III, intermediate-risk
histologyWT. It also highlighted the need to incorporate
biomarker and imaging research into a standardised
diagnostic and treatment protocol, the SIOP-RTSG
‘UMBRELLA 2016’ study [96]. The main research
objective of this upcoming study is to understand the
prognostic impact of somatic genetic biomarkers
(including 1q gain, TP53 mutation and MYCN aberra-
tions). Another aim is to optimise the definition of high-
risk ‘blastemal type’ WT by quantifying the volume of
blastemal components that survives pre-operative
chemotherapy and determining the correlation between
absolute blastemal volume, biomarkers and clinical
outcome [97]. A related aim is to identify molecular tar-
gets for novel therapeutic approaches, particularly for the
high-risk groups. Central pathology review will be
expanded across Europe in order to standardise di-
agnostics. Likewise, centralised radiology review will be
introduced, with a focus on better definition of computed
tomography (CT)-identified lung lesions and metastatic
response. Expanding the number of countries and centres
that participate is fundamental to collect sufficient bio-
logical material and clinicopathological data.6. Management of WT
6.1. Treatment
According to the SIOP-RTSG strategy, all patients with
WT aged over 6 months receive pre-operative chemo-
therapy with actinomycin D (ACT-D) and vincristine
(VCR). DOX is added in metastatic cases [5]. Pre-
operative chemotherapy reduces the risk of tumour
rupture thereby downstaging the tumour and decreasing
the overall burden of therapy [98]. Radical nephrectomy
is the current standard surgical treatment for children
with unilateral WT. For bilateral tumours or children at
high risk of bilateral disease, nephron sparing surgery
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disease, in order to preserve renal function without
compromising oncological risk, may play a role for
carefully selected patients in the future and guidelines
have been defined in consensus with the surgical experts
of the SIOP-RTSG group [96,99].
Following surgery, the histopathological features of
the tumour stratify patients into three prognostic
groups: low risk, intermediate risk and high risk (Table
2). The intensity of treatment is directed according to
these prognostic groups, based on previous studies
demonstrating the association between histopathology
and survival [97]. Post-operative chemotherapy and the
need for radiotherapy are further dictated by tumour
stage (Table 3 and Supplementary Fig. 1).
Survival rate for WT is nearly 90%. Nevertheless,
approximately 10% of patients with intermediate-risk
histology and up to 25% of patients with high-risk tu-
mours will relapse (Table 4) [5,100]. OS amongst relapsed
patients is around 50% but with a large variance depend-
ing on the initial treatment, relapse site and tumour his-
tology. These parameters guide future relapse treatment
into three risk categories (standard, high and very high
risk), where high-dosemelphalan andautologous stem cell
rescue are recommendedas consolidation inboth thehigh-
and very high-risk groups [101]. Relapse treatment, in
contrast to first line treatment, is not based on evidence
from RCTs, but solely on prospective single-arm studies
and, in very high-risk relapse, on case series [102e104].
6.2. Biomarkers
Currently, there is an increased focus on identifying better
prognosticmolecularmarkers forWT.RecommendationsTable 2
Comparison between histological subtyping and risk classification of WT
patients in each subgroup.
Source: SIOP WT 2001 database for all patients with stage IeIV WT, 573
van Tinteren, trial statistician. COG data from Ref. [166].of potential molecular markers in other tumour types are
mushrooming due to the low cost, speed and ease of cur-
rent genetic sequencing methods. Any potential prog-
nostic indicators require prospective validation and
assessment of intra-tumoural heterogeneity in a suitably
powered cohort of patients. Furthermore, even if a bio-
logical marker is independently found to be significantly
associated with clinical outcomes, the optimal adjustment
of treatment in subgroups of patients with and without
such markers is unknown.
Recently, the COG group assessed intensified (the
addition of etoposide [ETO]/cyclophosphamide [CYC] to
VCR/ACT-D and DOX) treatment for stage III/IV WT
with loss of heterozygosity (LOH) of 16q and 1p (w5% of
WT), which is associated with reduced OS [6,105].
Compared with a historical control group, they found
that the new 5 drug regimen significantly improved event-
free survival (EFS) and the intensified treatment is likely
to continue as standard for favourable histology WT
displaying LOH of 16q and 1p. Treatment was likewise
intensified for stage I and II patients, with DOX added to
VCR/ACT-D, though this did not significantly affect
outcome. This is the first group to use molecular bio-
markers to direct therapy in WT. A more common cy-
togenetic abnormality is gain of 1q, which is present in
about 30% of tumours and associated with worse EFS
and possible worse OS [106e108]. Likewise,MYCN gain
and 17p loss (the TP53 locus), limited to anaplastic WT,
may independently predict poor survival [27,31].
6.3. Late effects
Although associated with fewer late effects compared to
other solid malignant tumours, WT survivors still revealaccording to the SIOP and COG treatment approaches, with % of
1 patients were registered from 2001 to 2015. Data provided by Harm
Table 3
Comparison between staging classification for WT according to the SIOP and COG approaches.
Stage SIOP COG
I Tumour limited to kidney or surrounded with fibrous
pseudocapsule and completely resected.
Intrarenal vessel involvement may be present, no involvement
of renal sinus vessels. Presence of necrotic tumour in the renal
sinus or peri-renal fat does not upstage to stage II providing it
does not reach the resection margins.
Percutaneous cutting needle biopsy is allowed.
Tumour limited to kidney with intact renal capsule and
completely resected with no evidence of the tumour at or
beyond the margins of resection.
Intrarenal vessel involvement may be present, no involvement
of renal sinus vessels.
No biopsy has been performed.
II Tumour extension beyond kidney or renal pseudocapsule but
completely resected.
Infiltration of renal sinus and/or blood and lymphatic vessels
outside renal parenchyma but completely resected.
Local invasion of adjacent structures or extension into the vena
cava is allowed providing resection is performed en bloc and
there is no evidence of tumour at or beyond the resection
margins.
Tumour extension beyond kidney or penetration of renal
capsule but completely resected.
Local invasion of adjacent structures or extension into the vena
cava is allowed providing resection is performed en bloc and
there is no evidence of tumour at or beyond the resection
margins.
Absence of tumour rupture of spillage, even confined to the
flank.
No biopsy has been performed.
III Any of the following reasons, either individually or collectively,
assign a tumour to stage III: (1) tumour extends to or beyond
resection; margins microscopically or there is macroscopic
incomplete excision, (2) positive abdominal lymph nodes; (3)
tumour rupture before or intra-operatively including diffuse
peritoneal contamination by the tumour or where peritoneal
implants are present; (4) piecemeal removal of intravascular
tumour thrombus; (5) open biopsy prior to pre-operative
chemotherapy or surgery.
Any of the following reasons, either individually or collectively,
assign a tumour to stage III: (1) tumour extends to or beyond
resection margins microscopically or there is macroscopic
incomplete excision; (2) positive abdominal lymph nodes; (3)
tumour rupture before or intra-operatively including spillage
confined to the flank or diffuse peritoneal contamination by the
tumour or where peritoneal implants are present, (4) piecemeal
removal of intravascular tumour thrombus; (5) any biopsy is
performed prior to surgery.
IV Haematogenous metastases or distant lymph node metastases Haematogenous metastases or distant lymph node metastases
V Bilateral renal involvement at the time of initial diagnosis. Each
side’s tumour should be substaged separately according to
above criteria
Bilateral renal involvement at the time of initial diagnosis Each
side’s tumour should be substaged separately according to
above criteria.
COG, Children’s Oncology Group; SIOP, Socie´te´ Internationale d’Oncologie Pe´diatrique; WT, Wilms’ tumour.
Table 4
Two-year EFS and 5-year overall survival for WT in the SIOP 2001
protocol.
Histopathology
risk group
Stage I Stage II Stage III Stage IV All
Low (N) 95 6 23 61 185
2 y EFS (%) 97 100 100 91 95
5 y OS (%) 99 100 100 94 98
Intermediate (N) 1352 625 514 389 2880
2 y EFS (%) 92 89 88 81 89
5 y OS (%) 98 97 94 89 96
High (N) 163 115 141 75 494
2 y EFS (%) 91 84 68 31 74
5 y OS (%) 97 82 70 35 76
All (N) 1610 746 678 525 3559
2 y EFS (%) 92 88 84 76 87
5 y OS (%) 98 94 90 82 93
EFS, event-free survival; N, number of patients; OS, overall survival;
SIOP, Socie´te´ Internationale d’Oncologie Pe´diatrique; WT, Wilms’
tumour.
Source: SIOP WT 2001 database for all patients with stage IeIV
Wilms’ tumour treated as per-protocol with pre-op chemotherapy,
5731 patients were registered from 2001 to 2015. Analysis provided
by Harm van Tinteren, trial statistician.
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threatening health conditions in adult life [8]. The late
sequelae may include renal and cardiac dysfunction,
hypertension, musculoskeletal abnormalities, metabolic
syndrome, impaired fertility, reduced pulmonary func-
tion and secondary malignancies [7,109,110]. End-stage
renal failure is reported in 1% of unilateral WT and
about 10% of patients with bilateral disease at long-
term follow-up [111]. The risk of congestive heart fail-
ure increases with the cumulative dose of DOX
administered, with a critical threshold of 240 mg/m2.
Cardiotoxicity is potentiated by the concurrent use of
radiotherapy, with females and infants more susceptible
[109]. Similarly, DOX seems to potentiate the adverse
effects related to radiotherapy, likely due to its radio-
sensitisation of cells. These effects include abnormal
tissue growth within the target area and secondary
malignancies. In this context, omission of agents likely
to cause late effects is important to consider in treat-
ment optimisation. As mentioned previously, the last
trial, to demonstrate that a reduction in intensity was
acceptable, found DOX does not need to be added in
the treatment of stage IIeIII intermediate-risk WT [5].
Although this reduction marginally increases the risk of
J. Brok et al. / European Journal of Cancer 68 (2016) 179e195 187relapse, it likely outweighs the increased risk of severe
late effects as the small subset of children that relapse
can be rescued. Likewise, omission of lung radiotherapy
may also be an acceptable treatment approach for lung
lesions that have clearly responded to post-operative
chemotherapy [112].
6.4. Targeted therapy and immunotherapy
With our increased understanding of the aberrant mo-
lecular pathways that contribute to tumourigenesis
comes the drive to identify targeted therapeutics and
introduce a more personalised medicine approach.
Preclinical testing has shown that targeting the IGF
signalling pathway results in cell cycle arrest, with a
consequent reduction in tumour volume in transplanted
WT xenografts [113,114]. Despite these encouraging re-
sults, a phase II study assessing cixutumumab mono-
therapy (a monoclonal antibody [mAb] to IGF1R)
showed no objective response in refractory or relapsed
WT [115]. As this was a single-agent trial, the poor
response may be due to the complexity of IGF signalling
and its interaction with other oncogenic pathways [116].
As mentioned previously, theWNT/b-catenin pathway is
also frequently activated in WT and its downstream ef-
fectors play a general role in cancer progression [117].
Although drugs targeting WNT signalling have huge
potential, preclinical and clinical studies have not yet been
performed. Another promising target is MYCN, as
amplification of the oncogene is associated with reduced
survival in several childhood cancers including WT [31].
MYCN proteins have been considered undruggable until
the recent introductionof a class of inhibitors ofAuroraA
[30]. These inhibitors destabilise interactions between
Aurora A and MYCN and are being tested in several
adult phase I and II studies. The sole paediatric phase II
study using anAuroraAkinase inhibitor alisertib showed
an objective response in only 1 in 10 WT patients [118].
Despite the disappointing results from previous early-
phase studies in WT, there are several studies currently
recruiting for children with relapsed and refractory solid
tumours. Current trials include erlotinib, an epidermal
growth factor receptor (EGFR) inhibitor, ramucirumab, a
vascular endothelial growth factor receptor (VEGF) in-
hibitor, talazoparib, a PARP inhibitor and selinexor [119].
The field of immuno-oncology includes a spectrum of
interventions that encompass mAbs, cancer vaccines
and genetically engineered lymphocytes [120]. Early-
phase testing of immunotherapy for refractory and
relapsed childhood solid tumours is advancing. One
class of therapy to have garnered much attention is
antibodyedrug conjugates [121]. Lorvotuzumab mer-
tansine, a conjugate between a cytotoxic and an mAb to
CD56, showed impressive anti-tumour activity against
CD56-positive WT xenografts [122]. CD56 (NCAM-1)
is expressed in WT, enriched in blastema, and CD56þALDH-1þ cells may act as cancer-initiating stem cells in
a subset of tumours [123]. A phase II trial in children has
recently commenced [124]. A phase I study of the im-
mune checkpoint inhibitor ipilimumab, an anti-CTLA4
antibody that blocks the inhibitory signal to cytotoxic T
cells, has already been undertaken [125]. Finally, N-
glycosylated gangliosides, including NGcGM3 are an
attractive target, due to their expression on several
cancers including WT [126]. A phase I trial testing
racotumomab, a vaccine targeting NGcGM3, showed
immunogenicity and low toxicity, but further trials are
needed to assess response as the one patient with
anaplastic WT had progressive disease [127]. WT1 is a
major target for immunotherapy, given its oncogenic
role in several adult cancers, and promising results have
been demonstrated with dendritic cell vaccines and gene-
modified T-cell therapy [128,129]. Whether these ap-
proaches are transferrable to childhood WT remains to
be seen. To our knowledge, no trials have been con-
ducted in WT using adoptive engineered T or NK cells.
7. Treatment of non-WT
Overall, these tumours and their respective subtypes are
very rare and it remains challenging to gather robust
evidence for treatment recommendations. Hence, cross-
Atlantic collaboration, phase I/II studies and multina-
tional RCTs are extremely important to obtain useful
clinical data for these patients.
7.1. Clear cell sarcoma of the kidney
As per WT, patients registered on the SIOP-2001 trial
were treated with pre-operative chemotherapy. Post-
operative treatment consisted of ACT-D/VCR/DOX for
patients with local stage I disease and of ifosfami-
de(IFO)/ETO/carboplatin(CDC)/DOX for patients with
stage IIeIV disease, with irradiation of the flank for
stage II and III patients [130]. The 5-year overall EFS of
SIOP 93-01/2001 was 79% and the OS was 86%. Stage
IV disease and young age were significant adverse
prognostic factors for EFS [130e132].
The planned treatment for CCSK in the upcoming
‘UMBRELLA 2016’ study considers the best available
treatment to be ETO/CDC/DOX with alternating CYC/
IFO for any tumour stage. Flank radiotherapy will be
given to all patients with local stage II and III
tumours since the UK-WT-2 study revealed a high local
relapse rate in stage II patients treated without radio-
therapy [133]. For stage IV patients, if metastases are
unresectable, irradiation to metastatic sites will be given;
similarly, flank irradiation will be according to local stage.
Although outcomes for CCSK have improved, a
subgroup of patients do not fare well, including young
patients and those with advanced stage or relapsed dis-
ease. As treatment for CCSK is approaching the
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agents, new targeted therapies are necessary. Possible
targets include the Sonic Hedgehog signalling pathway
(SMO/GLI1 inhibitors), the PI3KeAkt signalling
pathway (PI3K inhibitors, Akt inhibitors, mTOR in-
hibitors), EGFR (erlotinib/gefitinib), BCOR (inhibition
of BCOR) and demethylating agents (e.g. decitabine).
Another possibility may be to inhibit the
YWHAEeNUTM2B/E fusion transcript but targeting
fusion transcripts has thus far proven to be difficult.
7.2. Malignant rhabdoid tumour of the kidney
Historically, patients with MRTK were treated as high-
risk WT, but currently, they are managed according to
rhabdoid tumour protocols. In SIOP 93-01/2001 trials,
most patients received pre-operative therapy with ACT-
D/VCR followed by post-operative chemotherapy,
consisting of ETO/CDC/IFO/DOX, and radiotherapy
but OS rates remained poor (25e30%) [134]. Similar
results have been observed using the North American
1e5 protocols [135]. Younger age was an important
adverse prognostic indicator and OS in infants was only
9% [135]. Overall, 30% of patients progressed during
initial therapy. A few case reports have demonstrated
effectiveness of regimens containing IFO/CDC/ETO
alternating with VCR/DOX/CYC in advanced disease
and some centres suggest high-dose therapy with stem
cell rescue based on these few patients [136e139].
MRTK patients will be treated according to the Euro-
pean Rhabdoid Registry (EU-RHAB) protocol with
DOX/IFO/CDC/ETO and VCR/CYC/Dactinomycin.
Children under 18 months of age will receive additional
CDC/thiotepa and stem cell rescue. Early complete
resection is important in the treatment of MRTK.
Novel therapeutic approaches are urgently required to
improve outcomes for patients with MRTK. Accumu-
lating evidence suggests that in its native form, the SWI/
SNF complex inhibits cell cycle progression by tran-
scriptionally repressing CCND1 (encodes cyclin D1) and
activating p16INK4A and p21CIP [140e142]. Based on this
observation, therapies targeting cyclin D1 and CDK4
have been tested in pre-clinical models of MRTK with
some evidence of activity [143]. Loss of SMARCB1 has
also been shown to activate expression of the mitotic
regulator Aurora A kinase and the Sonic hedgehog
pathway [144,145]. In addition, targets such as EZH2,
CXCR4, IGF2, PD-1/PD-L1 and the INI1 pathway
should be considered for future treatment strategies [146].
7.3. Renal cell carcinoma
Irrespective of subtype, the mainstay of therapy for
paediatric RCC is resection. Many patients with local-
ised, completely resected disease are cured without
adjuvant therapy. In translocation RCC, morphology
(Fuhrman grade) and distant metastatic disease wereassociated with poor survival [147]. In children, local
lymph node involvement seems not to be associated with
unfavourable outcome, even without adjuvant therapy
[148]. The need for radical node dissection still remains
to be determined [149]. Patient survival outcomes re-
ported in paediatric RCC patients are above 90% for
stage I and II, around 60% for stage III and around 30%
for stage IV [150,151].
Although there is no standard treatment for unresect-
able metastatic RCC in children, the approach is in
alignment with recently published adult RCC guidelines
[152]. High-dose interleukin-2 has had some success but
response is only observed for clear cell RCC [147,153].
Recent data on translocation RCC suggest that VEGF-
targeted therapy may be the best therapeutic option, with
sunitinib probably being the most effective [154,155].
Another relevant target is the mTOR pathway as high
levels of phosphorylated S6, a marker for mTOR activity
are found in RCC [73]. Patients who had progressive dis-
ease on VEGF therapy and were switched to mTOR in-
hibitors (evirolimus, temsirolimus) showed at least
transient disease stabilisation, including one with a partial
response. The fusion protein ASPLeTFE3 transactivates
the promoter of theMET receptor tyrosine kinase (RTK),
therefore inhibiting this RTK may be a potential therapy
for this type of translocation RCC [156]. Indications for
chemotherapy are extremely rare, but responses to gem-
citabine/DOX/oxaliplatin have been observed [148].8. Adult WT
WT is rare in patients over 16 years of age, with only 70
adults diagnosed in Europe each year [157]. The clinical
presentation in older patients is commonly flank pain and
weight loss. There are no specific adult treatment pro-
tocols but cure has been achieved using paediatric regi-
mens [158,159]. Adults have higher treatment-related
toxicity, with VCR neuropathy as the main adverse
event. Five-year survival is stage dependent; the largest
study showed variation from 74% for stage I disease to
less than 15% for metastatic tumours [157]. The poorer
prognosis may, in part, be explained by diagnostic delay.
Many adult WT patients are initially misdiagnosed as
there are no specific radiological findings to differentiate
WT from RCC. Central pathology review is recom-
mended as histological diagnosis can be challenging,
particularly for pathologists unfamiliar with paediatric
tumours. Best practice guidance, based on international
consensus, has been published to hasten time to start
adjuvant therapy and improve outcome [160].9. Challenging renal tumoursda patient with WT
For challenging patients, national and international
multidisciplinary expert panels are essential to advise
on optimum treatment and to minimise inequalities
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the upcoming European expert paediatric oncology
reference network projects, centres with expertise in a
particular treatment modality could be identified to
provide cross-border treatment of complex renal and
other tumours [161].
The most challenging renal tumours are predomi-
nantly the non-WT and WT that are high-risk histology,
bilateral, relapsed or refractory, metastatic and/or with
thrombus extension into the inferior vena cava. Each of
these scenarios occurs in about one in ten cases and
some patients may present with several concomitant
complex features. In the following clinical example, we
try to highlight some of the key decisions to consider
during treatment of complicated WT.
Example: A child with a clinical history of extended
abdomen, weight loss and haematuria. CT describes a
large solid/necrotic mass (volume w1100 ml) in the left
kidney with thrombus extension into the inferior vena cava
at suprahepatic level and three minor lesions in the right
kidney. No signs of rupture or abnormal lymph nodes or
spread to other organs. Chest considered clear but with a
single polygonal minor lesion (3 mm) in lower right pul-
monary lobe. Renal function is within the normal range.
Key issues at this stage would be 1) whether to treat
pre-operatively as metastatic due to the lung lesion and
add DOX to VCR/ACT-D, 2) to discuss surgical
approach with an experienced team due to thrombus
and bilateral disease, and 3) to consider diffusion
weighted MRI in order to better characterise the right-
sided renal lesions and the thrombus.
There remains great uncertainty surrounding the
interpretation and treatment of minor lung lesions
(<5mm) detected onCT, despitemany attempts to predict
the likelihood ofmetastatic disease, based on size, number,
appearance and locationof nodules [162].Accordingly, the
decision to add DOX pre-operatively is debatable. Owing
to this grey area, it is recommended to biopsy small lung
lesions of uncertain significance if feasible.
In cases with bilateral disease, the goal is to preserve
renal function without compromising the risk of relapse.
An experienced surgical team should discuss NSS versus
nephrectomy or biopsy of the right kidney for histology
to assess if the lesions only contain nephrogenic rests,
potentially negating the need for further surgery. For
patients with inferior vena cava thrombus extension, in
whom thrombectomy is considered, bypass support from
cardiothoracic surgeons is essential. An additional high-
quality diffusion-weighted MRI would be optimal to
reliably assess the extent of disease and to plan surgery.
After chemotherapy, pre-operative MRI illustrated
that the tumour size was unchanged and that liver lesions
had appeared. CT showed that the lung lesion was slightly
bigger (6 mm).
The key issue now is progressive disease. A decision
needs to be made whether to operate now, considering
the risks of challenging nephrectomy and thrombectomy,or whether to change and intensify chemotherapy with
the aim of reducing these risks. Pulmonary meta-
stastectomy in the same surgical se´ance should also be
considered.
Left nephrectomy including thrombectomy at week 7
was performed. Histopathology showed 25% necrosis and
viable tumour with mainly blastemal components (high-
risk) and lymph node with viable tumour (stage III). The
patient was started on the high-risk treatment protocol
and received local radiotherapy. Lung and liver lesions
were carefully monitored.
This patient represents a group with poor prognosis
due to chemo-resistant progressive blastemal disease.
Intensified chemotherapy, including DOX, and radio-
therapy are essential. The choice of intensified chemo-
therapy, or even high-dose chemotherapy with stem cell
rescue, remains in debate due to insufficient data from
case series. In future, this group of patients may well
benefit from a personalised medicine approach with
sequencing of their tumours undertaken to identify
actionable mutations and direct targeted therapy.10. Discussion
The treatment of WT is one of the successes of paedi-
atric oncology, with both the SIOP and COG ap-
proaches achieving cure in approximately 90% of
patients. The focus has now shifted to reducing thera-
peutic burden and the late effects related to anthracy-
clines and radiotherapy. A recent analysis of late
mortality in childhood cancer survivors showed that we
have already made progress, with a reduction in sec-
ondary neoplasms and cardiac events corresponding to
a reduction in treatment intensity [163]. Better risk
stratification is required to identify which subgroups of
patients can benefit from further treatment reduction.
In contrast, approximately 10% of children do not
survive WT, corresponding to at least 100 annual
deaths in Europe but with OS varying between Euro-
pean countries. Continued preclinical research is
needed to identify new agents for relapsed and re-
fractory WT, prior to testing their efficacy in early
phase trials. Targeted therapy has, so far, had less
promising results in clinical studies but the studies were
limited to small numbers of patients with tumours that
had not undergone genetic characterisation. Owing to
the complex interactions between signalling pathways
and resistance mechanisms, rational combination ther-
apies are needed. Treatment strategies will be influenced
by our improved understanding of Wilms’ tumouri-
genesis, gained through upcoming international studies
and the increasing numbers of tumours that will un-
doubtedly be sequenced over the next few years.
Genetic analysis of tumours and correlation with
clinicopathological characteristics can identify both
prognostic factors and potentially druggable targets.
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assessed through RCTs in order to gain robust evidence
for clinical practice. In some subgroups, the feasibility of
large trials is hampered by patient numbers, which
further stresses the need for expanding the number of
countries participating in SIOP and COG protocols and
for continued cross-Atlantic collaboration. It is impor-
tant that steering committees within each group
collaborate, prioritise and support the most relevant
research questions to be addressed. Treatment outcomes
in non-WT renal cancer have lagged behind and in
rhabdoid tumour, in particular, the prognosis remains
dismal. The numbers of children with these high-risk
tumours are insufficient to allow large RCTs, and to
circumvent this, COG and SIOP are collaborating on a
number of upcoming small studies.
Overall, more than half of all relapses in WT occur
in children in the intermediate-risk group, which in-
dicates that our current stratification methods need
refinement. Work is ongoing to identify tumour and
circulating biomarkers that have clinicopathological
associations and to validate these markers in interna-
tional studies. Follow-up for patients is currently
limited to clinical assessment and imaging for 2e5
years depending on stage and histology. The question
remains whether liquid biopsy has a role to play in non-
invasive monitoring and whether in future, it may be
used routinely to identify disease reoccurrence prior to
clinical relapse [164].
For 9 in 10 children diagnosed with a WT in Europe,
it is now a curable cancer. Continued effort is needed to
improve the poorer outcomes in high-risk metastatic
WT, relapsed WT and the high-risk non-Wilms’ renal
cancers. For this to be achieved requires the interna-
tional community to work together, both in the labo-
ratory and in paediatric oncology units.
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